{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}],"title":"PR"},{"measurements":[{"groupId":"OG000","value":"2"}],"title":"CR"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"description":"Defined as complete, or partial response, and progression-free survival. Measured by National Cancer Institute - Working Group and International Workshop on Chronic Lymphocytic Leukemia","groups":[{"description":"Ofatumumab will be infused intravenously on day 1 (300 mg initial dose), followed one week later by 2000 mg weekly for 7 doses, followed 4 weeks later by 2000 mg every 4 weeks for 4 doses. Two units (approximately 200 or 250 ml) of FFP will be administered prior to ofatumumab(with the exception of the first dose). A unit of fresh frozen plasma is approximately 250ml (or half a pint).\n\nOfatumumab + Fresh Frozen Plasma","id":"OG000","title":"Ofatumumab + Fresh Frozen Plasma"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Up to 37 months.","title":"Response to Therapy","type":"PRIMARY","unitOfMeasure":"Participants"}